STIMULAN®

Case study

Courtesy of Mr. Alan Norrish

Consultant Orthopaedic Surgeon; Mr Dimitrios Giotikas, Specialist Orthopaedic Surgeon, Cambridge, UK

Clinical particulars

35-year-old male presented with recurrent periprosthetic infection after complex hinged total knee replacement (TKR), performed 1 year ago, to treat severe post-traumatic knee osteoarthritis. 6 months after the initial procedure, he developed periprosthetic infection. Change of polyethylene, synovectomy, microorganism specific systemic antibiotics and repetitive arthroscopic lavage of the knee failed to control the infection.

Because of the knee stiffness and the compromised soft tissue condition, a revision TKR was not deemed appropriate so decision was made to treat infection with knee fusion.

Treatment

In order to preserve the length of the leg, a two-stage approach with the induced-membrane-technique was implemented. First stage, the implants were removed, necrotic and infected bone was excised and the knee was temporarily fused with a long Trigen nail. Normal length was preserved and the bone void filled with a PMMA spacer. Systemic antibiotics were administered. Second stage was conducted 3 months later, after clinical control of infection and normalisation of CRP and ESR values. The nail was exchanged to an osteobridge nail and bone graft was harvested with Reamer–Irrigator–Aspirator from the contralateral femur.
The bone graft and 10cc of STIMULAN mixed with antibiotic was inserted to fill the resulting dead space.

Outcome

7 months post-operatively, the infection remained controlled, the bone had consolidated and the patient had returned to daily activities without significant restrictions or symptoms. 2 years post-operatively, no recurrence of infection had occurred.



Presentation



Presentation



First stage -
Post operative



Second stage -
Post operative



7 months

For indications, contraindications, warnings and precautions see Instructions for Use. Concurrent use of locally administered antibiotics may affect setting time, absorption characteristics and/or bone formation. It is the surgeon/healthcare professional's responsibility to give due consideration to the details in the medicinal product marketing authorisation in deciding whether it is appropriate for the patient under his/her care. The relevant Summary of Product Characteristics (SmPC) must be consulted. The type and dose of medicinal substance should also be assessed according to the individual patient's clinical circumstance.

This brochure may include the use of STIMULAN or techniques that go beyond the current clearance/approval granted by the relevant regulatory authority. Please contact your local representative for further information.

Patents granted: GB2367552, EP 1204599 B1, US 6780391, EP 2594231 B1, US 88883063, CN ZL201210466117.X, GB2496710, EP 3058899 B1, US 10390954
Patents pending: GB1502655.2, US 15/040075, CN 201610089710.5, GB1704688.9, EP 18275044.8, US 15/933936, CN 108619579A

MA0066R4

Biocomposites®